SCHEMBL7711316

SCHEMBL7711316

CC1Oc2ccc(C(CC3CCCCC3)NC(=O)OC(C)(C)C)cc2NC1=S

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSS P25774 2/20 0.38
CTSK P43235 2/20 0.38
HSD17B1 P14061 1/20 0.37
HSD17B2 P37059 1/20 0.37
AAK1 Q2M2I8 2/20 0.35
CYP3A4 P08684 1/20 0.34
CACNA1B Q00975 2/20 0.33
REN P00797 6/20 0.33
KDM4E B2RXH2 2/20 0.33
ALDH1A1 P00352 2/20 0.33
RCE1 Q9Y256 1/20 0.33
PLA2G1B P04054 1/20 0.33
MAPT P10636 1/20 0.33
HPGD P15428 1/20 0.33
XBP1 P17861 1/20 0.33
HTT P42858 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
ATG4B Q9Y4P1 1/20 0.33
TSHR P16473 1/20 0.33
IDO1 P14902 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6998342 0.90 SMYD3 (0.40) CTSSCTSKHSD17B1HSD17B2AAK1
SCHEMBL7704943 0.82 ALDH1A1 (0.43) CTSSCTSKALDH1A1MAPTHPGD
SCHEMBL7095640 0.81 ALDH1A1 (0.37) KDM4EALDH1A1RCE1PLA2G1BMAPT
SCHEMBL6304809 0.81 MAPT (0.39) KDM4EALDH1A1RCE1PLA2G1BMAPT
SCHEMBL7092472 0.81 HSD17B10 (0.37) CACNA1BALDH1A1MAPTHPGDXBP1
SCHEMBL7087725 0.81 CTSS (0.41) CTSSCTSKALDH1A1MAPTHPGD
SCHEMBL7711322 0.80 MEN1 (0.38) CYP3A4KDM4EALDH1A1HPGDHTT
SCHEMBL7094044 0.80 SMN1; SMN2 (0.40) CACNA1BALDH1A1MAPTHPGDHTT
SCHEMBL7087735 0.79 MC4R (0.36) CTSKKDM4EALDH1A1RCE1PLA2G1B
SCHEMBL7095873 0.79 CTSS (0.42) CTSSCTSKKDM4EALDH1A1RCE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6365736-B1 TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. SCHERING AKTIENGESELLSCHAFT (DE) 2002-04-02 US disclosed